BENTYL
LOE ApproachingNDAORALCAPSULE
Approved
May 1950
Lifecycle
LOE Approaching
Competitive Pressure
30/100
Data completeness
2/8 — Basic
Drug data last refreshed 10h ago · AI intelligence enriched 2w ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
BENTYL is an oral capsule small molecule approved in 1950 for gastrointestinal indications. The drug's specific mechanism of action and therapeutic indications are not disclosed in available data. It is a legacy product approaching loss of exclusivity.
$0.051MPart D
LOE ApproachingMinimal commercial momentum with only $51K Part D spending and 39 claims in 2023; LOE approaching signals contraction and reduced investment in brand-building activities.
Mechanism of Action
Mechanism of action data is being enriched from DailyMed and FDA sources. Check back soon for updated drug intelligence.
Indications
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Career Relevance
Working on BENTYL offers limited career advancement opportunities given zero linked job openings and minimal commercial activity ($51K spending). Roles are primarily defensive, focused on optimizing margins and managing generic transition rather than driving growth or innovation.
Product Manager (Brand Management)Sales Representative
Worked on BENTYL at AbbVie? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.